Inhibitory effects of niclosamide on inflammation and migration of fibroblast-like synoviocytes from patients with rheumatoid arthritis

Inflammation Research

Volumn 64, Issue 3-4, 2015, Pages 225-233

  Liang, Liuqin ^a   Huang, Mingcheng ^a   Xiao, Youjun ^a   Zen, Shan ^a   Lao, Minxu ^a   Zou, Yaoyao ^a   Shi, Maohua ^a   Yang, Xiuyan ^a   Xu, Hanshi ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Fibroblast like synoviocytes; Inflammation; Migration; Niclosamide; Treatment

Indexed keywords

F ACTIN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE; NICLOSAMIDE; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOTAGMIN I; TUMOR NECROSIS FACTOR ALPHA; ANTICESTODAL AGENT; CYTOKINE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; TUMOR NECROSIS FACTOR;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL INVASION; CELL MIGRATION; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE SEVERITY; DOSE RESPONSE; DRUG MECHANISM; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; PHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SUPERNATANT; SYNOVIOCYTE; WESTERN BLOTTING; ANIMAL; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; CELL CULTURE; CELL MOTION; DBA MOUSE; DISEASE MODEL; DRUG EFFECTS; MALE; METABOLISM; MOUSE; PATHOLOGY; SYNOVIUM; TREATMENT OUTCOME;

ANIMALS; ANTICESTODAL AGENTS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; CELL MOVEMENT; CELLS, CULTURED; CYTOKINES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBROBLASTS; HUMANS; IN VITRO TECHNIQUES; INFLAMMATION; MALE; MICE; MICE, INBRED DBA; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NICLOSAMIDE; SIGNAL TRANSDUCTION; SYNOVIAL MEMBRANE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84925461239     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-015-0801-5     Document Type: Article

References (28)

1. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature. 2003;423:356–61.
2. Huber LC, Distler O, Tarner I, Gay RE, Gay S, Pap T. Synovial fibroblasts: key players in rheumatoid arthritis. Rheumatology (Oxford). 2006;45:669–75.
3. Mor A, Abramson SB, Pillinger MH. The fibroblast-like synovial cell in rheumatoid arthritis: a key player in inflammation and joint destruction. Clin Immunol. 2005;115:118–28.
4. Muller-Ladner U, Pap T, Gay RE, Neidhart M, Gay S. Mechanisms of disease: the molecular and cellular basis of joint destruction in rheumatoid arthritis. Nat Clin Pract Rheumatol. 2005;1:102–10.
5. Feldmann M. Pathogenesis of arthritis: recent research progress. Nat Immunol. 2001;2:771–3.
6. Roivainen A, Jalava J, Pirila L, Yli-Jama T, Tiusanen H, Toivanen P. H-ras oncogene point mutations in arthritic synovium. Arthritis Rheum. 1997;40:1636–43.
7. Yamanishi Y, Boyle DL, Green DR, Keystone EC, Connor A, Zollman S, et al. p53 tumor suppressor gene mutations in fibroblast-like synoviocytes from erosion synovium and non-erosion synovium in rheumatoid arthritis. Arthritis Res Ther. 2005;7:R12–8.
8. Lefevre S, Knedla A, Tennie C, Kampmann A, Wunrau C, Dinser R, et al. Synovial fibroblasts spread rheumatoid arthritis to unaffected joints. Nat Med. 2009;15:1414–20.
9. Ditzel J, Schwartz M. Worm cure without tears. The effect of niclosamide on taeniasis saginata in man. Acta Med Scand. 1967;182:663–4.
10. Osada T, Chen M, Yang XY, Spasojevic I, Vandeusen JB, Hsu D, et al. Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations. Cancer Res. 2011;71:4172–82.
11. Jin Y, Lu Z, Ding K, Li J, Du X, Chen C, et al. Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-κB pathway and generation of reactive oxygen species. Cancer Res. 2010;70:2516–27.
12. Balgi AD, Fonseca BD, Donohue E, Tsang TC, Lajoie P, Proud CG, et al. Screen for chemical modulators of autophagy reveals novel therapeutic inhibitors of mTORC1 signaling. PLoS One. 2009;4:e7124.
13. Wang AM, Ku HH, Liang YC, Chen YC, Hwu YM, Yeh TS. The autonomous notch signal pathway is activated by baicalin and baicalein but is suppressed by niclosamide in K562 cells. J Cell Biochem. 2009;106:682–92.
14. Chen M, Wang J, Lu J, Bond MC, Ren XR, Lyerly HK, et al. The anti-helminthic niclosamide inhibits Wnt/Frizzled1 signaling. Biochemistry. 2009;48:10267–74.
15. Sack U, Walther W, Scudiero D, Selby M, Kobelt D, Lemm M, et al. Novel effect of antihelminthic Niclosamide on S100A4-mediated metastatic progression in colon cancer. J Natl Cancer Inst. 2011;103:1018–36.
16. Wu CS, Li YR, Chen JJ, Chen YC, Chu CL, Pan IH, et al. Antihelminthic niclosamide modulates dendritic cells activation and function. Cell Immunol. 2014;288:15–23.
17. Wu CJ, Jan JT, Chen CM, Hsieh HP, Hwang DR, Liu HW, et al. Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide. Antimicrob Agents Chemother. 2004;48:2693–6.
18. Imperi F, Massai F, Ramachandran PC, Longo F, Zennaro E, Rampioni G, et al. New life for an old drug: the anthelmintic drug niclosamide inhibits pseudomonas aeruginosa quorum sensing. Antimicrob Agents Chemother. 2013;57:996–1005.
19. Volin MV, Huynh N, Klosowska K, Chong KK, Woods JM. Fractalkine is a novel chemoattractant for rheumatoid arthritis fibroblast-like synoviocyte signaling through MAP kinases and Akt. Arthritis Rheum. 2007;56:2512–22.
20. Gravallese EM, Manning C, Tsay A, Naito A, Pan C, Amento E, et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum. 2000;43:250–8.
21. King ML, Lindberg ME, Stodden GR, Okuda H, Ebers SD, Johnson A, et al. WNT7A/beta-catenin signaling induces FGF1 and influences sensitivity to niclosamide in ovarian cancer. Oncogene. http://www.nature.com/onc/journal/vaop/ncurrent/full/onc2014277a.html.
22. Wieland A, Trageser D, Gogolok S, Reinartz R, Hofer H, Keller M, et al. Anticancer effects of niclosamide in human glioblastoma. Clin Cancer Res. 2013;19:4124–36.
23. Sack U, Walther W, Scudiero D, Selby M, Kobelt D, Lemm M, et al. Novel effect of antihelminthic niclosamide on S100A4-mediated metastatic progression in colon cancer. J Natl Cancer Inst. 2011;103:1018–36.
24. Schett G, Tohidast-Akrad M, Smolen JS, Schmid BJ, Steiner CW, Bitzan P, et al. Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis. Arthritis Rheum. 2000;43:2501–12.
25. Han Z, Boyle DL, Aupperle KR, Bennett B, Manning AM, Firestein GS. Jun N-terminal kinase in rheumatoid arthritis. J Pharmacol Exp Ther. 1999;291:124–30.
26. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-κB activity. Annu Rev Immunol. 2000;18:621–63.
27. Baldwin AJ. The NF-κB and IκB proteins: new discoveries and insights. Annu Rev Immunol. 1996;14:649–83.
28. Huang C, Jacobson K, Schaller MD. MAP kinases and cell migration. J Cell Sci. 2004;117:4619–28.